Posted by Michael Wonder on 19 Mar 2026
Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis
19 March 2026 - Approval based on the positive GLISTEN Phase 3 trial with regulatory reviews underway in the EU, UK, Canada and China.
GSK today announced that the US FDA has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with PBC.
